Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.55 |
| ▸ | TK2 | O00142 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CDA | P32320 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.50 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.49 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25385069 | 0.84 | PYGM (0.61) | PYGMTK2SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL2580905 | 0.84 | PYGM (0.61) | PYGMTK2SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL5656890 | 0.82 | PYGM (0.58) | PYGMTK2MAPTCDASLC29A1 | |
| SCHEMBL5656888 | 0.82 | PYGM (0.58) | PYGMTK2MAPTCDASLC29A1 | |
| SCHEMBL16631629 | 0.82 | PYGM (0.52) | PYGMTK2SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL16631628 | 0.82 | PYGM (0.53) | PYGMTK2SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL16631584 | 0.82 | PYGM (0.51) | PYGMTK2SLC29A1SLC28A1SLC28A2 | |
| SCHEMBL16871785 | 0.81 | PYGM (0.57) | PYGMTK2MAPTCDASLC29A1 | |
| SCHEMBL7924237 | 0.81 | PYGM (0.57) | PYGMTK2MAPTCDASLC29A1 | |
| SCHEMBL16631545 | 0.80 | PYGM (0.56) | PYGMTK2SLC29A1SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1156583-C | Parallel ligand index concentration system generating method | ���ɿ�������˾ | 2004-07-07 | — | — | CN | disclosed |
| US-20030099945-A1 | Parallel selex | INVENUX, INC. (US) | 2003-05-29 | — | — | US | disclosed |
| CN-1367845-A | Parallel ligand index enrichment system generation method | INWENNACS CORP (US) | 2002-09-04 | — | — | CN | disclosed |
| EP-1115887-A4 | PARALLEL SELEX | INVENUX INC (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-1115887-A1 | PARALLEL SELEX | Invenux, Inc. (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6048698-A | PRODUCING PRODUCTS BY BOND FORMATION OF A REACTANT BOUND TO NUCLEIC ACID AND A FREE REACTANT, THEN CONTACTING PRODUCT LIBRARY WITH TARGET TO PARTITION PRODUCTS BY ABILITY TO PERFORM PRESELECTED FUNCTION | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-04-11 | — | — | US | disclosed |
| WO-2000017398-A1 | PARALLEL SELEX | INVENUX, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| US-5858660-A | FORMING PRODUCT LIBRARY BY CONTACTING TWO OR MORE REACTANTS WHERE ONE REACTANT IS COUPLED TO NUCLEIC ACID CAPABLE OF MEDIATING BOND FORMATION, SELECTING PRODUCTS HAVING PREDETERMINED CHARACTERISTICS | NEXSTAR PHARMACEUTICLAS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030099945-A1 | Parallel selex | SELE, MTREX, NSUN3 | PYGM 4211/4885TK2 2810/4885MAPT 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.